Ionis Pharmaceuticals 관리

관리 기준 확인 2/4

Ionis Pharmaceuticals CEO는 Brett Monia, Jan2020 에 임명되었습니다 의 임기는 5.08 년입니다. 총 연간 보상은 $ 12.50M, 7.7% 로 구성됩니다. 7.7% 급여 및 92.3% 보너스(회사 주식 및 옵션 포함). 는 $ 7.28M 가치에 해당하는 회사 주식의 0.14% 직접 소유합니다. 7.28M. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 8.7 년입니다.

주요 정보

Brett Monia

최고 경영자

US$12.5m

총 보상

CEO 급여 비율	7.7%
CEO 임기	5.1yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	5.1yrs
이사회 평균 재임 기간	8.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Brett Monia 의 보수는 Ionis Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$359m
Jun 30 2024	n/a	n/a	-US$366m
Mar 31 2024	n/a	n/a	-US$385m
Dec 31 2023	US$13m	US$961k	-US$366m
Sep 30 2023	n/a	n/a	-US$409m
Jun 30 2023	n/a	n/a	-US$309m
Mar 31 2023	n/a	n/a	-US$329m
Dec 31 2022	US$7m	US$825k	-US$270m
Sep 30 2022	n/a	n/a	US$7m
Jun 30 2022	n/a	n/a	-US$28m
Mar 31 2022	n/a	n/a	-US$4m
Dec 31 2021	US$13m	US$800k	-US$29m
Sep 30 2021	n/a	n/a	-US$608m
Jun 30 2021	n/a	n/a	-US$550m
Mar 31 2021	n/a	n/a	-US$495m
Dec 31 2020	US$11m	US$700k	-US$444m
Sep 30 2020	n/a	n/a	US$94m
Jun 30 2020	n/a	n/a	US$145m
Mar 31 2020	n/a	n/a	US$169m
Dec 31 2019	US$7m	US$528k	US$281m
Sep 30 2019	n/a	n/a	US$433m
Jun 30 2019	n/a	n/a	US$402m
Mar 31 2019	n/a	n/a	US$366m
Dec 31 2018	US$4m	US$508k	US$277m

보상 대 시장: Brett 의 총 보상 ($USD 12.50M )은 UK 시장( $USD 3.27M ).

보상과 수익: 회사가 수익성이 없는 동안 Brett 의 보상이 증가했습니다.

CEO

Brett Monia (63 yo)

5.1yrs

테뉴어

US$12,500,023

보상

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

리더십 팀

이름	위치	테뉴어	보상	소유권
Brett Monia	Founder	5.1yrs	US$12.50m	0.14% $ 7.3m
Elizabeth Hougen	Executive VP of Finance & CFO	12.1yrs	US$2.89m	0.070% $ 3.7m
B. Parshall	Director	7.1yrs	US$538.04k	0.055% $ 2.9m
Richard Geary	Executive VP & Chief Development Officer	16.5yrs	US$2.56m	0.063% $ 3.3m
Eric Swayze	Executive Vice President of Research	5.1yrs	US$2.56m	0.031% $ 1.6m
Darren Gonzales	Chief Accounting Officer & Senior VP	5yrs	데이터 없음	데이터 없음
C. Bennett	Executive VP & Chief Scientific Officer	5.1yrs	US$958.87k	0.059% $ 3.1m
D. Walke	Senior Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Patrick O'Neil	Executive VP	12.1yrs	US$3.92m	0.040% $ 2.1m
Hayley Soffer	Vice President of Corporate Communications	1.1yrs	데이터 없음	데이터 없음
Shannon L. Devers	Executive VP & Chief Human Resource Officer	5yrs	데이터 없음	0.010% $ 528.5k
Stanley Crooke	Scientific Advisor	3.7yrs	US$2.28m	데이터 없음

5.1yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 관리: 0JDI 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Brett Monia	Founder	5.9yrs	US$12.50m	0.14% $ 7.3m
B. Parshall	Director	24.4yrs	US$538.04k	0.055% $ 2.9m
Joan Herman	Independent Director	5.7yrs	US$540.04k	0.027% $ 1.4m
Joseph Klein	Independent Director	19.2yrs	US$542.04k	0.010% $ 545.7k
Joseph Wender	Lead Independent Director	31.1yrs	US$598.04k	0.084% $ 4.4m
Michael Hayden	Independent Director	6.4yrs	US$528.04k	0.024% $ 1.2m
Spencer Berthelsen	Independent Director	22.8yrs	US$548.04k	0.096% $ 5.0m
Joseph Loscalzo	Independent Chairman of the Board	11yrs	US$568.04k	0.020% $ 1.1m
Allene Diaz	Independent Director	3.7yrs	US$530.04k	0.010% $ 521.1k
Michael Yang	Independent Director	1.2yrs	US$363.05k	0.0012% $ 63.9k

8.7yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: 0JDI 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/02/06 15:07
장 마감 주가	2025/02/06 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Ionis Pharmaceuticals, Inc. 47 애널리스트 중 24 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ishan Majumdar	Baptista Research
Huidong Wang	Barclays
James Birchenough	Barclays

Ionis Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Founder recently sold US$430k worth of stock

Insufficient new directors

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Recent updates

Founder recently sold US$430k worth of stock

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves TRYNGOLZA (Olezarsen) as Addition to Diet to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Third quarter 2024 earnings released: US$0.94 loss per share (vs US$1.03 loss in 3Q 2023)

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $500.25 million.

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.45 loss per share (vs US$0.60 loss in 2Q 2023)

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings released: US$0.98 loss per share (vs US$0.87 loss in 1Q 2023)

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$2.56 loss per share (vs US$1.90 loss in FY 2022)

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$1.03 loss per share (vs US$0.33 loss in 3Q 2022)

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.74 loss in 2Q 2022)

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

First quarter 2023 earnings released: US$0.87 loss per share (vs US$0.46 loss in 1Q 2022)

Full year 2022 earnings released: US$1.90 loss per share (vs US$0.20 loss in FY 2021)

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.58 loss in 3Q 2021)

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen

Frederick Muto Retires from Ionis Pharmaceuticals, Inc., Effective July 15, 2022

Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Pharmaceuticals, Inc. Announces Results from the Phase 3 Valor Study and Its Open-Label Extension of tofersen

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.64 loss in 1Q 2021)

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022